The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight, Food & Drug Administration, 2024 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, New England Journal of Medicine (2023) Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis, Cardiovascular Diabetology (2019) Wegovy (semaglutide): A new weight loss drug for chronic weight management, Journal of Investigative Medicine (2022) Oral semaglutide, Clinical Diabetes (2020) Efficacy of semaglutide in a subcutaneous and an oral formulation, Frontiers in Endocrinology (2021) Wegovy Dosing Schedule, Novo Nordisk Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin, and digoxin in healthy subjects, Clinical Pharmacokinetics (2017) Metformin, MedlinePlus (2024) Common Side Effects of Wegovy, Novo Nordisk Updates about Wegovy, Novo Nordisk (2024) FAQs about Wegovy, Novo Nordisk Oral semaglutide versus empagliflozin in patients with Type 2 diabetes uncontrolled on metformin: The PIONEER 2 Trial, Diabetes Care (2019) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
That gives patients and clinicians a real sense of optimism. Looking ahead Further research will explore how these weight-independent effects work at a cellular level and whether similar benefits can be seen across different forms of what is sometimes known as fatty liver disease
A: Most forms of semaglutide, like Wegovy and Ozempic, are taken once weekly via injection
